| abstract |
The invention relates to new 2-substituted estra-1,3,5(10)-trien-17-ones of formula I n nas well as their pharmaceutically acceptable salts, their methods of manufacture and use as medicaments for prophylaxis and/or therapy of estrogen-dependent diseases that can be influenced by the inhibition of 17β-hydroxy steroid dehydrogenase type 1. |